NCT01981187

LGX818 for Patients With BRAFV600 Mutated Tumors

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Conditions

• Solid Tumor
• Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	LGX818	LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.

Timeline

• Start date: 2014-01-14
• Primary completion: 2015-09-01
• Completion: 2015-10-13
• First posted: 2013-11-11
• Last updated: 2021-03-26
• Results posted: 2021-03-26

Locations

13 sites across 1 country: United States